Glenmark Pharmaceuticals said that the company's US subsidiary Glenmark Generics Ltd. received US FDA approval for Ranitidine tablets of 150 mg and 300 mg tablets and would start distributing these products in US market.
Ranitidine tablets are indicated in treatment of pathological hypersecretory conditions, the short-term treatment and maintenance of gastric ulcer patients, treatment of GERD and the treatment and maintenance of erosive esophagitis. It had sales in excess of $41 million for the 12-month period ended June 2008 as per IMS data.
For comments and feedback: editorial@rttnews.com